article · Pharmaceutical Development and Technology
studies demonstrated significant augmentation in oral hypoglycemic activity of EMPA, revealed as 1.45-fold elevation in area under blood glucose reduction curve after administration of SMEDDS compared to EMPA aqueous dispersion. SMEDDS formulation successfully improved intestinal absorption, hypoglycemic efficacy and hence oral bioavailability of EMPA.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/10837450.2026.2674731
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
